IP Group is among the investors backing the DDR cancer therapeutics developer’s latest round, which took its total funding to $320m.

Artios Pharma, a UK-based cancer therapy developer, secured $153m in a series C round on Tuesday from investors including commercialisation firm IP Group.
Investment firms Omega Funds and TCG Crossover co-led the round, which included the corporate venture capital units of pharmaceutical firms Merck Group, Novartis and Pfizer – M Ventures, Novartis Venture Fund and Pfizer Ventures.
Avidity Partners, Invus, Deep Track Capital, Sofinnova Partners, Tetragon Financial Group, RTW Investments, Soleus Capital, Piper Heartland Healthcare Capital, CaaS Capital…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
email
Linked in